Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.
Kim A PappSaskia de VenteJiewei ZengMary FlackByron PadillaStephen K TyringPublished in: Dermatology and therapy (2021)
ClinicalTrials.gov identifier; NCT02203851.